Publications by authors named "A Prentakis"
Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson's Disease and Asymptomatic Carriers of Related Genes: A Brief Report.
Medicina (Kaunas)
July 2023
Article Synopsis
- Previous research indicates a connection between malignant melanoma (MM) and Parkinson's disease (PD), suggesting shared molecular mechanisms could underlie this link.
- The study examined the prevalence of MM among 1,416 PD patients, 275 healthy controls, and 670 asymptomatic carriers of PD-related genes, focusing on those with a medical history of MM.
- Findings revealed 46 PD patients with a history of MM, with genetic mutations in the LRRK2 and GBA genes present in some cases, but no correlation was found between these mutations and MM development in symptomatic or asymptomatic individuals.
Background: The role of blood uric acid as a biomarker in symptomatic motor PD has been increasingly established in the literature.
Objective: Our present study assessed the role of serum uric acid as a putative biomarker in a prodromal PD cohort [REM Sleep Behavior disorder (RBD) and Hyposmia] followed longitudinally.
Methods: Longitudinal 5-year serum uric acid measurement data of 39 RBD patients and 26 Hyposmia patients with an abnormal DATSCAN imaging were downloaded from the Parkinson's Progression Markers Initiative database.
Introduction: Higher prevalence of motor and non-motor features has been observed in non-manifesting mutation carriers of Parkinson's Disease (PD) compared to Healthy Controls (HC). The aim was to detect the differences between GBA and LRRK2 mutation carriers without PD and HC on neuropsychiatric symptoms.
Methods: This is a cross-sectional retrospective study of non-manifesting GBA and LRRK2 mutation carriers and HC enrolled into Parkinson's Progression Markers Initiative (PPMI).
Background: Previous studies have highlighted serum uric acid as a putative idiopathic Parkinson's disease (iPD) biomarker. Only one study, so far, showed higher levels of serum uric acid in leucine-rich repeat kinase 2 (LRRK + 2) carriers compared to those who developed PD, however a longitudinal comparison between LRRK2 + PD and healthy controls (HC) has not been performed.
Objective: The aim of this study was to determine whether there are longitudinal differences in serum uric acid between iPD, LRRK2 + PD and HC and their association with motor and non-motor features.
Introduction: Blood uric acid represents an important biomarker in sporadic Parkinson's disease (PD). Whether uric acid levels change in genetic forms of PD is beginning to be assessed. The aim of the present study was to evaluate differences in serum uric acid level among PD patients harboring mutations in the glucocerebrosidase (GBA1) gene, sporadic PD, and healthy controls followed longitudinally.
View Article and Find Full Text PDF